Associations Between Short-Term Ambient Particulate Matter Exposure and The Risk of Severe COVID-19 (preprint)

Background: Previous studies have suggested the relation between outdoor air pollution and the onset risk of Corona Virus Disease 2019 (COVID-19). However, there is a lack of data related to the severity of the disease, especially in China. Methods We recruited a group of COVID-19 patients diagnosed in a recent large-scale outbreak caused by Delta variants in eastern China. We collected ambient air pollution data of the same period where the case occurred and applied a generalized linear model (GLM) to analyze the effects of short-term outdoor ambient particulate matter (PM) exposure on the risk of severe COVID-19. Results A total of 476 confirmed adult patients were recruited, of which 42 (8.82%) had a severe illness. With a unit increase in PM 10 , the risk of severe COVID-19 increased by 47.64% (95% confidence interval [CI]: 27.67, 70.73) at lag 0-14 days, 65.00% (95% CI: 35.18, 101.40) at lag 0-21 days, and 69.44% (95% CI: 37.03, 109.50) at lag 0-28 days, respectively. The association remained significant at lag 0-14 days or 0-28 days in the multi-pollutant models. With a unit increase in PM 2.5 , the risk of severe COVID-19 increased by 49.47% (95% CI: 19.61, 86.78) at lag 0-14 days, 97.61% (95% CI: 45.92, 167.60) at lag 0-21 days, and 120.27% (95% CI: 56.53, 209.98) at lag 0-28 days, respectively. The association remained significant at lag 0-21 days or 0-28 days in the multi-pollutant models. Conclusions Our results indicated that short-term exposure to outdoor PM was positively related to the risk of severe COVID-19, and reducing air pollution may contribute to the control of COVID-19.

The efficacy and safety of Chinese traditional medicine injections on patients with coronavirus disease 2019: A protocol for systematic review and meta analysis.

INTRODUCTION: The pandemic caused by the coronavirus disease 2019 (COVID-19) infection has exposed vulnerable populations to an unprecedented global health crisis. Research reported that Chinese traditional medicine injections were used in patients with COVID-19 infection and showed significant effects, and there have been no systematic review and meta-analyses to investigate the effects and safety of Chinese traditional medicine injections. MATERIALS AND METHODS: This systematic review and meta-analysis protocol is based on the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols 2015 statement. The literature search will involve Cochran library, Web of science, PubMed, MEDLINE, Embase, China Biology Medicine Database, China National Knowledge Infrastructure Database, VIP, Wang Fang database, and China Clinical Trial Registration Center for articles and research published form December 2019. This search will include randomized controlled trials and nonrandomized studies. The Cochrane Collaboration's tool for randomized controlled trial studies and the Quality Assessment Tool for Quantitative Studies for nonrandomized studies will be used to assess the risk of bias among the studies included in the systematic review. Review Manager 5.3 software will be used for the meta-analysis, and odds ratio are calculated as the primary outcomes. Subgroup analyses will then be performed based on the characteristics of the interventions and populations included in the studies examined. ETHICS AND DISSEMINATION: This systematic review protocol is designed to provide evidence regarding the effects and safety of Chinese traditional medicine injections on patients with COVID-19, such evidence may be useful and important for clinical treatment decisions. The results should be disseminated through publication in a peer-reviewed journal. Since the data and results used in the systematic review will be extracted exclusively from published studies, approval from an ethics committee will not be required.

The effectiveness and safety of traditional Chinese medicine for the treatment of children with COVID-19.

INTRODUCTION: With the widespread spread of novel coronavirus pneumonia, more and more countries have been affected. Some research reports have shown that traditional Chinese medicine has a significant effect on COVID-19 infection, and the treatment of traditional Chinese medicine is used in some special people, such as children. At present, there is a lack of high-quality systematic reviews on the safety and efficacy of using Chinese medicine to treat children with novel coronavirus pneumonia. MATERIALS AND METHODS: We will search Cochran library, MEDLINE, EMBASE, China National Knowledge Infrastructure Database (CNKI), China Biomedical Database (CBM), VIP Database (VIP), and Wanfang database for research. This study includes randomized controlled trials (RCTs) and non-RCTs, and uses the Cochrane systematic review to review the safety and efficacy of traditional Chinese medicine in preventing and treating children with novel coronavirus pneumonia. RCT research tools and quantitative research quality assessment tools for non-randomized studies will be used to assess the risk of bias in studies included in the systematic review. We will use Revman 5.3 software for meta-analysis, the main result is odds ratio, and then a subgroup analysis will be performed based on the age, intervention degree, and disease severity of the patients reviewed. ETHICS AND DISSEMINATION: This systematic review protocol is designed to provide evidence regarding the effectiveness and safety of traditional Chinese medicine for the treatment of children with COVID-19, such evidence may be useful and important for clinical treatment decisions. The results should be disseminated through publication in a peer-reviewed journal. Since the data and results used in the systematic review will be extracted exclusively from published studies, approval from an ethics committee will not be required. REGISTRATION INFORMATION: PROSPERO CRD42020179150.